BCL2 and breast carcinoma: It also induced the downregulation of BCRP1 and potential target genes, including RET, ERBB4, SOX2, FN1, HES1, VIM, PCNA, and BCL2, and elevated the mRNA levels of TP53 and CASP7. In addition, molecular docking revealed that HON inhibits RET, ErbB4, and Notch signaling to overcome TAM resistance in breast cancer cells.